Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.

Oncotarget - 1 Jan 2015

Petti Consalvo, Picco Gabriele, Martelli Maria Luisa, Trisolini Elena, Bucci Enrico, Perera Timothy, Isella Claudio, Medico Enzo

Abstract excerpt

Constitutively active receptor tyrosine kinases (RTKs) are known oncogenic drivers and provide valuable therapeutic targets in many cancer types. However, clinical efficacy of RTK inhibitors is limited by intrinsic and acquired resistance. To identify genes conferring resistance to inhibition of the MET RTK, we conducted a forward genetics screen in the GTL-16 gastric cancer cell line, carrying MET amplification...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Sulfones
Share to Gene Library
Share to Indoles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Neoplasm Transplantation

Share to Proto-Oncogene Proteins c-met

Share to raf Kinases

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 25473895
DOI: 10.18632/oncotarget.2771
PMCID: PMC4381590

Genes

MET
BRAF
RAF1
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.PMID 25473895Read ↗

<i>MET</i> and <i>KRAS</i> Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

Drug resistance in targeted cancer therapies with RAF inhibitorsSemantic proximity Read ↗

Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.Semantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.Semantic proximity Read ↗

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinomaSemantic proximity Read ↗

Amplification of <i>MET</i> may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Semantic proximity Read ↗

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibitionSemantic proximity Read ↗

Understanding and overcoming innate and acquired MAPK-inhibition resistance in anaplastic thyroid cancerSemantic proximity Read ↗

The role of MET in chemotherapy resistanceSemantic proximity Read ↗

An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.